STAT+: Pharmalittle: AstraZeneca Covid-19 vaccine shows promise in elderly; surprise rule will require insurers to estimate out-of-pocket drug costs
Top of the morning to you and a fine one, it is. Blue skies and crisp breezes are enveloping the serene Pharmalot campus this morning, where the short person remains hunched over a laptop and the official mascot is sprinting about the grounds in search of creatures. This means we are happily focused on the important matters at hand — brewing cups of stimulation (blueberry is our choice today) and foraging for items of interest. On that note, here are a few. May today be productive, satisfying, and safe. Meanwhile, do keep in touch. …
The Covid-19 vaccine developed by the University of Oxford and AstraZeneca (AZN) produces a strong immune response in healthy adults 56 to 69 years old and people over 70, The Telegraph telegraphs. Phase 2 data, published in The Lancet, suggests one of the groups most vulnerable to serious illness and death from Covid-19 could build immunity. There were also fewer serious side effects than in younger volunteers. Phase 3 trials of the vaccine are ongoing, with early efficacy readings possible in the coming weeks.
Continue to STAT+ to read the full story…
